Q-omics provides the consensus-scored NTM-IT profile across patient tissues and cancer cell-line models. NTM-IT expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, NTM-IT is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, NTM-IT RNA expression shows 12,313 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, LUSC, and GBM as cancer lineages where NTM-IT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NTM-IT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NTM-IT survival associations across molecular data types. NTM-IT RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NTM-IT RNA expression–survival associations across cancer types. High NTM-IT expression shows unfavorable associations in UCS, BLCA, UCEC, LUSC, LAML and THCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for NTM-IT RNA expression.
This table summarizes NTM-IT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for NTM-IT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NTM-IT shows lower tumor expression in LUSC and higher tumor expression in HNSC. The LUSC box plot shows higher NTM-IT RNA expression in normal versus tumor tissue (log2 FC = −0.038, t-test p = .001).
This table shows molecular features associated with NTM-IT in patient tissues and cancer cell lines. In patient samples, NTM-IT shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
